From: CD44/CD24 Expression in recurrent gastric cancer: a retrospective analysis
Characteristics | Study Group | Control Group |  P -value |
---|---|---|---|
 | (n = 20) | (n = 20) |  |
 | Recurrence | Non-recurrence |  |
Gender, n(%) | |||
Male | 12 (60.0) | 7 (35.0) | 0.113†|
Female | 8 (40.0) | 13 (65.0) | Â |
Age (years) | |||
mean ± SD | 71.2 ± 10.6 | 65.7 ± 11.7 | 0.128‡ |
Age group, n(%) | |||
≤65 | 6 (30.0) | 10 (50.0) | 0.197†|
>65 | 14 (70.0) | 10 (50.0) | Â |
Histology, n(%) | |||
Moderately differentiated (intestinal type) | 9 (45.0) | 6 (30.0) | 0.327†|
Poorly differentiated (diffuse type) | 11 (55.0) | 14 (70.0) | Â |
Tumor location, n(%) | |||
Upper third of stomach | 5 (25.0) | 10 (50.0) | 0.191¶ |
Middle third of stomach | 1 (5.0) | 0 (0.0) | Â |
Lower third of stomach | 14 (70.0) | 10 (50.0) | Â |
TNM Stage, n(%) | |||
I-IIa | 4 (20.0) | 15 (75.0) | 0.001*†|
III-IV | 16 (80.0) | 5 (25.0) | Â |
Lymph node metastasis, n(%) | |||
No | 2 (10.0) | 11 (55.0) | 0.002*†|
Yes | 18 (90.0) | 9 (45.0) | Â |
Number of lymph node metastasis, n(%) | |||
0 | 2 (10.0) | 11 (55.0) | 0.007*†|
1-4 s | 9 (45.0) | 6 (30.0) |  |
≥5 | 9 (45.0) | 3 (15.0) |  |
CD44 expression, n(%) | |||
CD44- | 10 (50.0) | 10 (50.0) | 1.000†|
CD44+ | 10 (50.0) | 10 (50.0) | Â |
CD24 expression, n(%) | |||
CD24- | 10 (50.0) | 13 (65.0) | 0.337†|
CD24+ | 10 (50.0) | 7 (35.0) | Â |
CD44 / CD24 expression, n(%) | |||
CD44-/CD24- | 5 (25.0) | 8 (40.0) | 0.622¶ |
CD44-/CD24+ | 5 (25.0) | 2 (10.0) | Â |
CD44+/CD24- | 5 (25.0) | 5 (25.0) | Â |
CD44+/CD24+ | 5 (25.0) | 5 (25.0) | Â |